654 related articles for article (PubMed ID: 18413769)
1. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
2. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
3. Abortive activation precedes functional deletion of CD8+ T cells following encounter with self-antigens expressed by resting B cells in vivo.
Fraser JM; Janicki CN; Raveney BJ; Morgan DJ
Immunology; 2006 Sep; 119(1):126-33. PubMed ID: 16796693
[TBL] [Abstract][Full Text] [Related]
4. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA
J Immunol; 1998 Jan; 160(2):643-51. PubMed ID: 9551898
[TBL] [Abstract][Full Text] [Related]
5. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
6. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
7. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors.
Hermans IF; Daish A; Yang J; Ritchie DS; Ronchese F
Cancer Res; 1998 Sep; 58(17):3909-17. PubMed ID: 9731502
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
9. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
10. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
Gaffal E; Schweichel D; Tormo D; Steitz J; Lenz J; Basner-Tschakarjan E; Limmer A; Tüting T
Eur J Cell Biol; 2007 Dec; 86(11-12):817-26. PubMed ID: 16928407
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells.
Westendorf AM; Fleissner D; Deppenmeier S; Gruber AD; Bruder D; Hansen W; Liblau R; Buer J
Gastroenterology; 2006 Aug; 131(2):510-24. PubMed ID: 16890605
[TBL] [Abstract][Full Text] [Related]
13. Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes.
Leggatt GR; Narayan S; Fernando GJ; Frazer IH
J Leukoc Biol; 2004 Oct; 76(4):787-95. PubMed ID: 15240746
[TBL] [Abstract][Full Text] [Related]
14. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
15. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
16. Donor cell persistence and activation-induced unresponsiveness of peripheral CD8+ T cells.
Ehl S; Barchet W; Oehen S; Aichele P; Hombach J; Hengartner H; Zinkernagel RM
Eur J Immunol; 2000 Mar; 30(3):883-91. PubMed ID: 10741405
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
19. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
20. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]